- Home
- ELBM vs EDSA Comparison
ELBM vs EDSA Comparison
Compare ELBM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELBM
- EDSA
- Stock Information
- Founded
- ELBM 2011
- EDSA 2015
- Country
- ELBM Canada
- EDSA Canada
- Employees
- ELBM N/A
- EDSA N/A
- Industry
- ELBM Industrial Machinery/Components
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- ELBM Miscellaneous
- EDSA Health Care
- Exchange
- ELBM Nasdaq
- EDSA Nasdaq
- Market Cap
- ELBM 16.7M
- EDSA 15.4M
- IPO Year
- ELBM N/A
- EDSA N/A
- Fundamental
- Price
- ELBM $0.86
- EDSA $2.53
- Analyst Decision
- ELBM Strong Buy
- EDSA Strong Buy
- Analyst Count
- ELBM 1
- EDSA 2
- Target Price
- ELBM $2.20
- EDSA $13.00
- AVG Volume (30 Days)
- ELBM 130.6K
- EDSA 19.8K
- Earning Date
- ELBM 08-15-2025
- EDSA 08-08-2025
- Dividend Yield
- ELBM N/A
- EDSA N/A
- EPS Growth
- ELBM N/A
- EDSA N/A
- EPS
- ELBM N/A
- EDSA N/A
- Revenue
- ELBM N/A
- EDSA N/A
- Revenue This Year
- ELBM N/A
- EDSA N/A
- Revenue Next Year
- ELBM N/A
- EDSA N/A
- P/E Ratio
- ELBM N/A
- EDSA N/A
- Revenue Growth
- ELBM N/A
- EDSA N/A
- 52 Week Low
- ELBM $0.77
- EDSA $1.55
- 52 Week High
- ELBM $2.70
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- ELBM 26.53
- EDSA 67.77
- Support Level
- ELBM $0.84
- EDSA $2.26
- Resistance Level
- ELBM $0.93
- EDSA $2.51
- Average True Range (ATR)
- ELBM 0.07
- EDSA 0.13
- MACD
- ELBM -0.01
- EDSA 0.02
- Stochastic Oscillator
- ELBM 26.15
- EDSA 93.94
About ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.